Abstract. Our previous studies demonstrated that high expression of oncoprotein 18 (Op18)/stathmin promotes malignant transformation of non-small cell lung cancer NCI-H1299 cells. Investigation of the cellular settings determined that NCI-H1299 cells were genetically p53 deficient. In order to determine whether p53 deficiency is associated with Op18/stathmin-mediated high levels of malignancy, exogenous wild-type p53 (p53wt) was introduced into NCI-H1299 cells in the present study to observe Op18/stathmin signaling changes and malignant behaviors. The results indicated that p53 downregulated Op18/stathmin expression and phosphorylation at the Ser25 and Ser63 sites in NCI-H1299 cells, and the abilities of proliferation, colony formation and migration in multi-dimensional spaces were simultaneously reduced. Introduction of p53 wt inhibited the expression of the transcription factor nuclear factor-κB (NF-κB), and the activities of the Op18/stathmin upstream kinases cyclin-dependent 2 (CDC2) and extracellular signal-regulated kinase (ERK). Furthermore, blocking of NF-κB signaling decreased CDC2 and ERK activation. Additionally, p53 intervention attenuated the secretion and protein expression of the immune inhibitory cytokine interleukin-10, which was in accordance with the effect of NF-κB signaling inhibition. Further experiments validated that p53 enhanced the sensitivity of NCI-H1299 cells to Taxol through initiating the caspase-3 and -9 intrinsic death pathways, and resulted in cell cycle arrest at the G1/S phases. These data indicated that exogenous p53wt mediates the regulation of Op18/stathmin signaling through the p53-NF-κB-CDC2/ERK-Op18/stathmin pathway, and that p53 deficiency is associated with high malignancy levels of NCI-H1299 cells.

Introduction In our previous study, 5 epithelial-derived carcinoma cell lines, including human non-small cell lung cancer (NSCLC) NCI-H1299, human nasopharyngeal carcinoma CNE1, human gastric cancer MGC, human breast cancer MCF-7 and human hepatoma Hep3b-2, were used to screen Taxol-resistant cells. The results confirmed that NCI-H1299 cells highly expressing oncoprotein 18 (Op18)/stathmin exhibited resistance to Taxol, and strong capabilities of cell proliferation, migration and invasion, compared with the other cell lines (1). Silencing of Op18/stathmin by RNA interference (RNAi) resulted in inhibition of cell proliferation and motility, and strengthened the sensitivity of NCI-H1299 cells to Taxol. In vivo experiments confirmed that RNAi of Op18/stathmin combined with Taxol co-operatively decreased the tumorigenesis of transplanted NCI-H1299 cells and tumor growth, and promoted high-grade differentiation of xenografts (2). By tracing the genetic background of NCI-H1299 cells and retrieving relative literatures, it was determined that NCI-H1299 cells are innately p53 deficient, and lack p53 protein expression (3,4). We hypothesized that p53 deficiency is associated with the high malignancy levels of NCI-H1299 cells exhibiting high expression of Op18/stathmin.

Wild-type p53 (p53wt) prevents cell cycle progression and the repair of damaged and mutant genes, and induces apoptosis and inhibition of proliferation in tumor development. p53wt is activated and highly expressed in instances of DNA damage caused by stress, including ultraviolet radiation, hypoxia and drugs, promotes the sensitivity of tumors to treatment and increases cell apoptosis (5,6). The majority of antitumor drugs induce p53 expression and activation; for example, in colon cancer HCT-116 cells with p53wt introduced, Adriamycin enhanced p53 expression and inhibition of cell proliferation (7). Similarly, high concentrations of Nutlin-3 induced high expression of p53 resulting in apoptosis in colon cancer RKO and prostate cancer LNCaP cells with p53wt, and the status of cell apoptosis was positively associated with the levels of p53 expression (8).
The microtubule regulator Op18/stathmin, a small molecule of phosphoprotein that is highly expressed in solid tumors, serves a crucial role in integrating and transducing various signals from intra- and extra-cellular stimuli (9). It directly regulates the dynamics equilibrium of the microtubule cytoskeleton, and controls cellular biological behavior, including cell cycle progression, metastasis and invasion, through phosphorylated inactivation and dephosphorylated activation (9-11). Co-transfection of Op18/stathmin luciferase reporter and p53wt carrier confirmed that p53wt inhibited the promoter of Op18/stathmin, which resulted in decreased Op18/stathmin mRNA transcription and protein expression, and arrested the cell cycle at the G2/M phases in HT1080 fibrosarcoma cells (12).

The present study is a continuation of our previous research which primarily focused on investigating whether p53wt deficiency was associated with Taxol resistance mediated by Op18/stathmin signaling in NCI-H1299 cells. Additionally, the changes in Taxol resistance following the introduction of exogenous p53wt and the molecular mechanism regulating Op18/stathmin signaling was investigated to determine the effects of exogenous p53wt on Op18/stathmin signaling and the underlying molecular mechanisms, and the association between p53 deficiency and the malignancy of NCI-H1299 cells was confirmed.

Materials and methods

Cell lines and cell culture. The NSCLC NCI-H1299 cell line [American Type Culture Collection (ATCC), Manassas, VA, USA; ATCC number, CRL-5803™] was grown in RPMI-1640 medium (cat. no. 01-100-1ACS; Biological Industries, Kibbutz Beit Haemek, Israel) supplemented with 10% fetal bovine serum (FBS; cat. no. 04-001-1ACS; Biological Industries), 100 IU/ml penicillin and 100 µg/ml streptomycin (cat. no. SV30010; HyCone; GE Healthcare Life Sciences, Logan, UT, USA) at 37°C in humidified atmosphere containing 5% CO₂.

Antibodies and chemical reagents. The primary antibodies comprised of rabbit polyclonal anti-stathmin (1:3,000; cat. no. 569391; EMD Millipore, Billerica, MA, USA), anti-extracellular signal-regulated kinase 1 (ERK1; 1:1,000; cat. no. sc-93), anti-cyclin-dependent 2 (CDC2; 1:1,000; cat. no. sc-954), anti-nuclear factor-xB (NF-xB; 1:1,000; cat. no. SC-109), anti-B-cell lymphoma-2 (Bel-2; 1:1,000; cat. no. sc-492), mouse monoclonal anti-β-actin (1:2,000; cat. no. sc-47778), anti-phospho(Thr)-ERK1 (1:1,000; cat. no. sc-7383), anti-caspase-3 (1:1,000; cat. no. sc-7272), anti-p53 (1:1,000; cat. no. sc-126), anti-Bcl-2-associated X protein (1:1,000; Bax; cat. no. sc-7480) (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), mouse monoclonal anti-caspase-8 (1:1,000; cat. no. 9746), rabbit monoclonal anti-caspase-9 (1:1,000; cat. no. 9052), rabbit polyclonal anti-p-thr161-CDC2 (1:1,000; cat. no. 9114) (Cell Signaling Technology, Inc., Danvers, MA, USA), anti-p-stathmin Ser25 (1:1,000; cat. no. ab194752), anti-p-stathmin Ser63 (1:1,000; cat. no. ab76583), anti-interleukin-10 (IL-10; 1:1,000; cat. no. ab34843) and anti-IL-6 (1:1,000; cat. no. ab6672) (Abcam, Cambridge, MA, USA).

The secondary antibodies used were horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (which was diluted at 1:3,000 for the detection of stathmin, NF-xB, IL-6 and IL-10, and at 1:2,500 for detecting caspase-9, Bel-2, p-stathmin-Ser25, -Ser63, phospho-Thr161-CDC2, CDC2 and ERK; cat. no. sc-2004) and rabbit anti-mouse IgG (which was diluted at 1:3,000 for the detection of β-actin and p53, and at 1:2,500 for analyzing caspases-3, -8, Bel-2-associated X and phosphor-ERK; cat. no. sc-358914) (Santa Cruz Biotechnology, Inc.).

The NF-xB inhibitor ammonium pyrrolidine dithiocarbamate (PDTC; cat. no. 5108-96-3; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) (13) and Taxol (cat. no. sc-201439; Santa Cruz Biotechnology, Inc.) were separately dissolved in dimethyl sulfoxide (DMSO), stored at -20°C and diluted to appropriate concentrations (Taxol, 100 nM; or PDTC, 5 or 10 µM) prior to use.

Plasmid construction and cell transfection.Nearly confluent cells at the logarithmic growth phase were divided into three groups (blank, C3 and p53wt) for transfection as follows: Blank control without any plasmid (blank); empty vector pEGFP-C3 (C3); and pEFGP-C3-p53 (p53wt). The plasmid pEGFP-C3-p53 was constructed by inserting the p53wt gene into the pEGFP-C3 vector between the two cleavage sites of Xhol and KpnI, and PEGFP-C3 was labeled with neomycin and kanamycin resistance genes. G418 (400 µg/ml; Sigma-Aldrich; Merck KGaA) was used to screen cells following transfection for 5 h. The PEGFP-C3 and pEGFP-C3-p53 plasmids were provided by Professor Cao Ya (Cancer Research Institute, Central South University, Changsha, China).

Cell transfection was performed with Lipofectamine® 2000 (cat. no. 11668-019; Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocols. Additionally 4 µg plasmids in 10 µl Lipofectamine 2000 were transiently transfected into cells at a transfection efficiency of >80% in 250 µl incomplete RPMI-1640 medium.

Western blot analysis. Protein was extracted with lysis buffer consisting of 50 mM pH 8.0 Tris-HCl, 1 mM ethylenediaminetetraacetic acid, 2% SDS, 5 mM dithiothreitol and 10 mM phenylmethylsulfonyl fluoride. The protein concentration was determined using BCA Protein Assay Reagent (Pierce; Thermo Fisher Scientific, Inc.). Total proteins (50 µg) were then separated by 10% SDS-PAGE and electro-transferred onto nitrocellulose membranes. The membranes were blocked with phosphate-buffered saline (PBS) containing 5% non-fat milk overnight at 4°C, incubated with the aforementioned primary antibodies overnight at 4°C, and then with the aforementioned HRP-conjugated secondary antibodies for 2 h at room temperature. An enhanced chemiluminescence detection kit (Thermo Fisher Scientific, Inc.) was used for immunoblotting. Protein belts were exposed on the films in a dark room, then scanned and saved for the edition by Photoshop 7.0 software (Adobe Systems Inc., San Jose, CA, USA).

MTT assay. Cells (5x10³ cells/well) were seeded in a 96-well plate and each sample was placed in 6 parallel wells. A total of 10 µl 5 mg/ml MTT (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) was added to each well for 4 h for
24, 48 or 72 h. The supernatant was then discarded, 100 µl DMSO was added and the plate was shaken with a Transference Decoloring Shaker (ZD-2008; Haimen Kylin-Bell Instrument Manufacturing Co., Ltd., Shanghai, China) at a fixed low speed at room temperature for 10 min. The optical density (OD) value was measured using a microplate reader (BioTek Instruments, Inc., Winooski, VT, USA) at a wavelength of 490 nm. The relative proliferative ratio of the cells per well was calculated according to the following formula: Relative proliferation (%) = (ODtransfection/ODcontrol) x 100%. The relative proliferative ratio of the blank control was set as 100% at all time points.

Colony formation analysis. Cells were seeded in media at a density of 2x10^3 cells/well in 6-well plates (2 parallel wells/sample) for ~2 weeks at 37°C in an incubator with an atmosphere containing 5% CO_2_. When clear colonies were observed by the naked eye, the plates were washed three times with PBS and fixed with 100% methanol for 15 min at room temperature. The cells were then stained with crystal violet for 15 min at room temperature and washed with water to remove excess dye. Colonies containing >50 cells were counted under a light inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany) at x100 magnification. Colony formation rate (%) = (means number of colonies/2000) x 100%. The experiment was repeated three times.

Wound healing assays. Cells were cultured overnight at 37°C in an atmosphere containing 5% CO_2_ to yield a monolayer in 6-well plates, and then the monolayer was scratched using 200-µl pipette tips, washed twice with PBS and RPMI-1640 medium was added. Wound healing status was monitored at 0, 12, 24 and 36 h, and images were captured with an inverted light microscope at x4 magnification in order to analyze the capability of cell migration in the 2-dimensional plane.

Transwell assays. The upper chambers of a Transwell plate with 8.0 µm pore size of polycarbonate membrane of polystyrene plates (cat. no. 3422; Costar, Corning Incorporated, Corning, NY, USA) were pretreated with heated serum-free RPMI-1640 medium for 30 min at 37°C and then the medium was removed. Cells were adjusted to a concentration of 2x10^5 cells/ml in RPMI-1640 medium with 0.2% FBS. A total of 200 µl sample was added to the upper chamber, and the lower chamber was filled 800 µl RPMI-1640 medium with 10% FBS. The plates were incubated at 37°C for 24 h. The upper chamber was removed, the medium was discarded and a cotton swab was used to remove cells on the bottom of the upper chamber. The remaining migrated cells on the back of the membrane in the bottom of upper chamber were fixed with 100% methanol for 10 min at room temperature and stained with 0.1% crystal violet for 10 min at room temperature for Transwell analysis in 3-dimensional space. Images were captured in 5 random visual fields under an inverted light microscope at x40 magnification. Experiments were repeated three times.

ELISA assays of autocrine IL-10 and IL-6. A total of 1x10^6 cells/well were incubated in 24-well plates containing serum-free incomplete RPMI-1640 medium without the special indicator phenol red. After 24 h at 37°C, the supernatant was collected for detection of autocrine IL-10 and IL-6 levels from the tumor cells using ELISA.

The absorbance value was measured at a wavelength of 450 nm with the Human IL-10 (cat. no. EK1102) and Human IL-6 (cat. no. EK1106) ELISA kits [Hangzhou Multi Sciences (Lianke) Biotech Co., Ltd., Hangzhou, China], according to the manufacturer's protocols.

Fluorescence-activated cell sorting (FACS) analysis. Cells were washed with ice-cold PBS and digested with 0.25% trypsin. Cells were collected for centrifugation at 697 x g for 5 min at room temperature, and the pellet was suspended with PBS as a single-cell solution, which was centrifuged at 697 x g at room temperature and washed twice with PBS. Cells were resuspended with 300 µl PBS and fixed with 70 µl 70% ethanol at 4°C overnight for the detection of cell cycle distribution and apoptosis.

Cell cycle distribution and apoptosis were detected using FACS, which was performed by a specialized institute (Beijing Dingguo Changsheng Biotechnology Co., Ltd., Beijing, China).

Statistics. Statistical analysis was performed using the statistical software SPSS, version 17.0 (SPSS, Inc., Chicago, IL, USA). Data were presented as the mean ± standard deviation. Analysis of variance and least significant difference method were applied to perform multiple comparisons between the groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Introduction of p53wt decreases Op18/stathmin expression and phosphorylation. Western blotting for p53 demonstrated that the p53wt lane exhibited a band while the blank and the C3 lanes did not exhibit any trace of p53, which demonstrated that the NCI-H1299 cells were originally p53-deficient, and that exogenous p53wt was successfully introduced and expressed in the cells. There were no differences in the expression between the blank and the C3 controls, but the expression of Op18/stathmin was notably impaired in the p53wt group, compared with the two control groups (Fig. 1A).

Similarly, the levels of Op18/stathmin phosphorylation at the Ser25 and Ser63 sites were notably decreased in the p53wt lane, compared with the two control groups, and there were no evident changes in the expression between the blank and C3 control groups (Fig. 1B).

Figure 1. Introduction of exogenous p53wt decreases Op18/stathmin expression and phosphorylation of NCI-H1299 cells. (A) Successfully expressed p53 downregulates the levels of Op18/stathmin in NCI-H1299 cells. (B) p53 inhibits Op18/stathmin phosphorylation at the Ser25 and Ser63 sites. Op18, oncoprotein 18; p53wt, wild-type p53; C3, pEGFP-C3.
**p53** impairs the capabilities of cell proliferation and colony formation. Cell proliferation curves demonstrated that the relative proliferation ratios were 96.5, 96.3 and 96.2% in the C3 control group at the 24, 48 and 72 h time points, respectively, which were similar to the blank group, that was set as 100% at all time points. Compared with the two approximately parallel curves for the blank and C3 control groups, the representative curve for the p53wt group descended steeply with proliferation ratios of 83.5, 72.9 and 59.9% at the three time points, respectively (Fig. 2A). The histograms demonstrated that no statistical difference existed between the blank and C3 control groups at the three time points, but the relative proliferation ratio of the p53wt group was significantly reduced, compared with the other groups (P<0.01). The difference between the ratios of the two control groups was not significant (Fig. 2B).

Colony formation analysis demonstrated that a number of large colonies composed of several small colonies with merging borders, as depicted in the blank and C3 control groups. By contrast, there were only a few sparsely distributed small colonies in the p53wt group (Fig. 2C). The mean colony formation ratios, which implied the mean percentage of forming colonies (>50 cells) in 2,000 cells, were 10.65 and 10.23% in the two control groups, respectively, and 6.62% in the p53wt group, which was significantly reduced, compared with the other groups (P<0.01). The difference between the ratios of the two control groups was not significant (Fig. 2D).

**p53** suppresses cell migration in multi-dimensional spaces. The wound healing assays demonstrated that a large proportion of the scratched area remained empty among all three groups at the 12 h time point. After 24 h, the wound width of the C3 group was reduced, compared with the blank group, but the difference was not notable by the naked eye. The wounds
had almost healed at 36 h in the blank and C3 control groups; however, a large area of the scratched region remained empty in the p53wt group. p53wt introduction inhibited the migration of NCI-H1299 cells in the 2-dimensional plane (Fig. 3A). The Transwell assays identified that the mean number of migrated cells was 28, 26 and 14 among the blank, C3 and p53wt groups, respectively. Therefore, the number of migrated cells was significantly reduced in the p53wt group, compared with the two control groups; therefore, p53wt significantly reduced the motility of cells in 3-dimensional space (P<0.01; Fig. 3C).

p53 negatively modulates the activities of CDC2 and ERK by inhibiting NF-κB expression. Western blotting indicated that p53 expression successfully attenuated CDC2 phosphorylation at the thr161 site. The levels of ERK and p-ERK were also downregulated in the p53wt group, but those of CDC2 were similar among the three groups (Fig. 4A). Additionally, introduction of exogenous p53wt reduced the expression of NF-κB (Fig. 4B).

The NF-κB inhibitor PDTC was employed to block NF-κB signaling in p53-deficient NCI-H1299 cells. Western blot analysis demonstrated that the levels of p-thr161-CDC2, ERK and p-ERK, with ERK being slightly decreased at 5 µM, compared with at 0 µM and notably reduced at 10 µM, while p-ERK gradually decreased in a PDTC concentration-dependent manner. Blockage of NF-κB signaling also downregulated the activities of p-thr161-CDC2 and ERK, which is in agreement with the results of p53 introduction, and the concentration gradient of PDTC did not exert any effects on CDC2 expression (Fig. 4C).

p53 inhibits IL-10 autocrine and protein expression. ELISA confirmed that the mean autocrine IL-10 OD level in the culture supernatant was 0.109, 0.093 and 0.055 in the blank, C3 and p53wt groups, respectively. The mean level of the p53wt group was significantly decreased, compared with the two control groups (P<0.01), and there was no significant difference between those of the blank and C3 control groups (Fig. 5A). ELISA demonstrated that IL-6 autocrine OD levels were low in the three groups and p53 did not affect IL-6 (Fig. 5B).

Western blot analysis demonstrated that IL-10 was expressed normally in the blank and C3 control groups, which
was similar between them, but was notably attenuated in the p53wt group. Additionally, IL-6 was not expressed in the three groups (Fig. 5C).

Concentration gradients of the inhibitor PDTC down-regulated the expression of IL-10 in a concentration-dependent manner in NCI-H1299 cells, which implied that blockage of NF-κB signaling induced the identical inhibitory effects on IL-10 expression as exogenous p53wt induction (Fig. 5D).

**Discussion**

*p53* is a tumor suppressor gene that primarily arrests aberrant cells at the G1/S phase checkpoint for repair of damaged DNA, which results in apoptosis when the degree of destroyed DNA is beyond the threshold of repair (5). Mutation of *p53* that occurs in the majority of tumors results in failure to control cell growth, apoptosis and DNA repair, and ultimately becomes a tumor-promoting gene that induces carcinogenesis and drug resistance (14). There are >50% of tumors that exhibit p53 mutation; therefore, utilization of p53wt against tumors is an attractive treatment strategy (15,16).

Our previous studies confirmed that silencing Op18/stathmin would result in the inhibition of cell migration and invasion in NCI-H1299 cells following the introduction of exogenous p53wt (1,2). The present study confirmed that the introduction of exogenous p53wt successfully inhibits Op18/stathmin expression and phosphorylation, and decreases the capacities of proliferation and colony formation, as well as migration in multi-dimensional spaces in NCI-H1299 cells. In melanoma A375, Hs294T and G361 cells, a previous study also determined that increased p53 expression...
Figure 6. Analysis of growth and apoptosis in NCI-H1299 cells following p53 introduction. (A) The upper images depict the status of cell growth and the lower panels depict the cell cycle distribution and apoptosis ratios of the three groups as determined by fluorescence-activated cell sorting assays. (B) p53 initiates the activation of caspase-3 and -9. (C) p53 decreases Bcl-2 expression levels and increases Bax expression levels. Original magnification, x10. p53<sup>wt</sup>; C3, pEGFP-C3; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X.

Figure 7. p53 induction promotes the sensitivity of NCI-H1299 cells to Taxol. The upper panel depicts the cell growth, and the lower panel depicts the FACS analysis of Taxol treatment. Original magnification, x10. p53<sup>wt</sup>; C3, pEGFP-C3.
resulted in inhibition of cellular growth and viability following treatment with the histone deacetylase sirtuin type 1 inhibitor Tenovin-1 (17).

The present study specifically demonstrated the status of Op18/stathmin expression and its phosphorylation following the introduction of exogenous p53<sup>wt</sup>; however, further experiments primarily indicated the changes of regulatory molecules CDC2, ERK and NF-κB on Op18/stathmin signaling for the intervention of exogenous p53<sup>wt</sup> which negatively modulated the activities of CDC2 and ERK by inhibiting NF-κB expression. CDC2 is a positive regulator of the cell cycle process, in which aberrant activation is associated with acceleration of cell proliferation and malignant transformation in the development of tumors (18-20). ERK is a major member of the mitogen-activated protein kinases family, and is also involved in the positive regulation of cell proliferation and differentiation (21,22). In Epstein-Barr virus (EBV)-infected nasopharyngeal carcinoma CNE1 cells, Op18/stathmin was identified as the downstream target of CDC2 and ERK, and EBV-encoding latent membrane protein 1 promotes cell cycle progression through the regulation of CDC2- and ERK-mediated Op18/stathmin signaling (23,24). Previous studies indicated that Op18/stathmin was dephosphorylated in NCI-H1299 cells treated with the CDC2 blocker purvalanol A or ERK blocker PD98059, both of which enhance the sensitivity of cells to Taxol (25,26). Due to the activity of Op18/stathmin regulating microtubules being regulated by the balance of phosphorylation and dephosphorylation, the phosphorylation levels of Op18/stathmin at the Ser25 and 63 sites following the introduction of p53<sup>wt</sup> were detected. The present study demonstrated that exogenous p53<sup>wt</sup> expression inhibits the phosphorylation of CDC2-thr161 and ERK, downregulates the activities of CDC2 and ERK kinases, and negatively regulates Op18/stathmin phosphorylation at the Ser25 and Ser63 sites. The decreased phosphorylation of Op18/stathmin was associated with the downregulation of Op18/stathmin expression and the loss of the activities of its upstream kinases, ERK and CDC2, following exogenous p53<sup>wt</sup> introduction.

The transcription factor NF-κB is associated with cell proliferation, and blocking of NF-κB signaling results in inhibition of tumor growth (27,28). In the present study, introduction of exogenous p53<sup>wt</sup> decreased the expression levels of NF-κB and the activities of CDC2 and ERK, while PDTC blocking of NF-κB signaling also resulted in decreased levels of CDC2 and ERK activity in the NCI-H1299 cells. These results demonstrated that p53 negatively regulates the activation of CDC2 and ERK via NF-κB, and indirectly influences Op18/stathmin expression and phosphorylation. Therefore, p53 regulates Op18/stathmin signaling through the p53-NF-κB-CDC2/ERK-Op18/stathmin pathway.

IL-10 is a pleiotropic cytokine and is considered as an immunosuppressor that mediates tumor immune evasion through inhibition of the host immune response, therefore serving a vital role in tumor survival and metastasis (29). IL-6 is also a multi-functional cytokine secreted by a variety of cell types and is frequently involved in a series of physiological and pathological effects, including inflammation and fibrosis (30). Aberrant expression of IL-6 is associated with the poor prognosis of patients with glioma (31), and gallbladder and colon cancer types (32,33). The effects of p53<sup>wt</sup> on the release of autocrine cytokines IL-10 and IL-6 and their protein expression levels in NCI-H1299 cells were also investigated in the present study, which indicated that p53 inhibits IL-10 in vitro autocrine and protein expression, but does not exert any influence on IL-6. We hypothesized that p53-mediated Op18/stathmin signaling is implicated in the immune evasion of tumors via autocrine IL-10. However, IL-6 autocrine and expression remained at low levels in the NCI-H1299 cells with or without exogenous p53. A previous study reported that autocrine IL-10 suppressed the production of pro-inflammatory cytokines, including tumor necrosis factor-α, IL-1 and IL-6, and further mediated immune evasion by inhibiting the ability of antigen-presenting cells to present antigens to T cells (33).

Caspase-3 and -9 are the executor and promoter of the endogenous cell death pathway, respectively (25). Bcl-2 is an anti-apoptotic protein and Bax primarily acts against the anti-apoptotic activity of Bcl-2 (25,35,36). In the present study, p53 upregulated the expression levels of caspase-3 and -9, and Bax, and decreased the levels of Bcl-2 expression in NCI-H1299 cells. p53 resulted in cell cycle arrest at the G<sub>S</sub>/S phases and an increase in cell apoptosis, enhancing the sensitivity of NCI-H1299 cells to Taxol, which indicates that the lack of p53 is associated with the development of Taxol resistance in NCI-H1299 cells with high expression of Op18/stathmin. Introduction of exogenous p53<sup>wt</sup> resulted in a majority of cells arresting at the G<sub>S</sub>/S phases, but the ratios of NCI-H1299 cells halted at the G<sub>S</sub>/S phases was only slightly reduced following the co-treatment of p53<sup>wt</sup> and Taxol, which may be associated with Taxol primarily inducing cells arresting at the G<sub>G</sub>/M phase, eventually causing a decrease of G<sub>S</sub> stage cells following the synergistic induction of p53<sup>wt</sup> and Taxol, compared with the treatment of p53<sup>wt</sup> alone (37).

Acknowledgements
The authors would like to thank Professor Cao Ya from the Cancer Research Institute of Central South University (Changsha, China) for providing the plasmids.

Funding
This study was financed by the Key Scientific Research Project of Colleges and Universities of Hunan Province (grant no. 12A018), the National Natural Science Foundation of China (grant no. 81272274) and the Natural Science Foundation of Hunan Province (grant no. 12JJ3104).

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions
XL was primarily responsible for the design of the study and the revision of the manuscript. The experiments, analysis and interpretation of the data were primarily conducted by SC. Members of the research team also included YZ, FS, DL and TY, who participated in part of the experiments, analysis and...
interpretation of the data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


